Indivior Pharmaceuticals, Inc. 8-K

What Happened

• Indivior Pharmaceuticals, Inc. announced on May 4, 2026 that it issued a press release and furnished that release with the SEC on Form 8-K. The disclosure was made under Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events) and the press release is included as Exhibit 99.1 to the Current Report.

Key Details

• Filing date: May 4, 2026 (Form 8-K).
• SEC items cited: Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events).
• Exhibit: Press release furnished as Exhibit 99.1 to the Form 8-K.
• Item 9.01 noted the inclusion of exhibits in the filing.

Why It Matters

• This 8-K confirms Indivior publicly released information on May 4, 2026 and followed Regulation FD procedures to ensure broad disclosure. Investors should review Exhibit 99.1 (the press release) for the specific content and any potentially material information that could affect the company’s outlook or stock price. Check Indivior’s investor relations page or the SEC EDGAR filing for the full press release and any subsequent filings.